Chapter
Clozapine and other SGAs for treatment resistance
Combinations of antipsychotic drugs
Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS)
Maintenance treatment (see Fig. 2.2 for outline)
choice of the antipsychotic drug in maintenance treatment
Duration of relapse prevention with antipsychotic drugs
The optimal dosage in maintenance treatment
Chapter 3 Evidence-based pharmacotherapy of bipolar disorder
Pharmacotherapy of bipolar depression
Pharmacotherapy of mania and mixed episodes
Pharmacotherapy of relapse prevention
Chapter 4 Evidence-based pharmacotherapy of major depressive disorder
First-line treatment for MDD
SSRIs vs. tricyclic antidepressants (TCAs)
SSRIs vs. newer-generation antidepressants
Subpopulations and predictors of response
Symptom severity at baseline
Patients at risk of suicide
Timing of clinical improvement
Continuation and maintenance treatment
Treatment-resistant depression
Antidepressant augmentation
Additional antidepressants
S-adenosyl methionine (SAMe)
Chapter 5 Evidence-based pharmacotherapy of panic disorder
Importance of adequate care
Available pharmacological evidence
Efficacy in acute phase treatment
Efficacy in long-term treatment
Side-effects and risks involved
Efficacy in comorbid conditions
Efficacy in acute phase treatment
Efficacy in long-term treatment
Side-effects and risks involved
Efficacy in comorbid conditions
Optimal first-line pharmacotherapy
Optimal duration of pharmacotherapy
Optimal approach to pharmacotherapy in the treatment-refractory patient
Chapter 6 Evidence-based pharmacotherapy of social anxiety disorder
What is the first-line treatment for social anxiety disorder?
Summary of published clinical trials
Monoamine oxidase inhibitors (MAOIs)
Reversible inhibitors of monoamine oxidase-A (RIMAs)
Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs)
Escitalopram and citalopram
Use of meta-analysis as a basis for evidence-based practice
Meta-analysis of Gould and colleagues (1997)
Meta-analysis of Van der Linden and colleagues (2000)
Meta-analysis of Fedoroff and Taylor (2001)
Blanco and colleagues (2003b)
Hedges and colleagues (2007)
Chapter oice of medication
How long should treatment last?
What is the management of treatment-resistant cases?
Reasons for treatment resistance
Augmentation with medication
The treatment of non-generalized SAD
Treatment of SAD in children
Chapter 7 Evidence-based pharmacotherapy of generalized anxiety disorder
Response rates in acute treatment studies
Prediction of response to pharmacological treatment
Optimal duration of continuation treatment
Management after non-response to initial treatment
Pregnancy and breastfeeding
Chapter 8 Evidence-based pharmacotherapy of obsessive-compulsive disorder
First-line treatments for OCD: Clomipramine
SRIs compared with other antidepressants lacking strong serotonergic activity
Placebo-controlled studies of fluvoxamine
Placebo-controlled studies of sertraline
Placebo-controlled studies of fluoxetine
Placebo-controlled studies of paroxetine
Placebo-controlled studies of citalopram
Placebo-controlled studies of escitalopram
Have Chapter anges in study populations affected treatment trial design?
Direct head-to-head comparisons of SRIs in OCD
Improved tolerability favors SSRIs
Meta-analyses of relative effectiveness of SRIs in OCD
Suicide in children on SSRIs
What is the most effective dose?
Strategies for dose titration in OCD
Do SSRIs improve health-related quality of life?
Criteria for treatment response and relapse
Other pharmacological treatments
How long should treatment be continued?
Long-term efficacy studies
Relapse prevention studies
What is the best dose for long-term treatment?
Predictors of treatment response
Preferred options if poor response to first-line treatment
Altering mode of delivery
Combining SSRIs and drugs exerting antidepressant or anxiolytic properties
Combining SSRIs with drugs with antipsychotic properties
First-generation antipsychotics
Second-generation antipsychotics (Table 8.5)
Long-term adjunctive antipsychotics
Combining SSRIs with other agents
Adjunctive behavior therapy
Chapter 9 Evidence-based pharmacotherapy of post-traumatic stress disorder
Monoamine oxidase inhibitors
Reversible inhibitors of monoamine oxidase A (RIMAs)
Selective serotonin reuptake inhibitors
Tricyclic antidepressants (TCAs)
Review of meta-analyses of pharmacotherapy for PTSD
Meta-analysis of pharmacotherapy for PTSD
Treatment-refractory cases
Chapter 10 Evidence-based pharmacotherapy of eating disorders
Antipsychotics (Table 10.1)
Antipsychotics in children and adolescents
Tricyclic antidepressants (TCAs)
Selective serotonin reuptake inhibitors (SSRIs) (Table 10.2)
SSRIs in children and adolescents
Mood stabilizers and anticonvulsants
Medications that improve gastric emptying (prokinetic agents)
Other medications in children and adolescents (Table 10.3)
Monoamine oxidase inhibitors (MAOIs)
SSRIs for BN in children and adolescents
Mood stabilizers and anticonvulsants (Table 10.5)
Other medications (Table 10.6)
Norepinephrine uptake inhibitors and serotonin norepinephrine reuptake inhibitors
Mood stabilizers and anticonvulsants (Table 10.8)
Antiobesity medications (Table 10.9)
First-line pharmacotherapy for EDs
American Psychiatric Associations guidelines
National Institute for Clinical Excellence (NICE) guidelines
Evidence for maintenance treatment
Best approaches for treatment resistance
Conclusions and future directions for research
Chapter 11 Evidence-based pharmacotherapy of nicotine and alcohol dependence
Full nAchR agonists: nicotine replacement therapy (NRT)
Partial nAchR agonists (varenicline, cytisine)
nAchR antagonist (mecamylamine)
Antidepressants (nortriptyline, bupropion, St Johns wort)
Opioid receptor antagonists
Cannabinoid receptor antagonists
Alpha2-norepinephrine agonists
Conclusion: nicotine dependence treatment
Opioid receptor antagonists (naltrexone/nalmefene)
Glutamatergic medications (acamprosate, topiramate)
Gamma hydroxybutyric acid (GHB)
Conclusion: alcohol dependence treatment
Chapter 12 Evidence-based pharmacotherapy of illicit substance use disorders
Medication directed at total abstinence
Methadone maintenance treatment (MMT)
Buprenorphine with or without naloxone
Heroin-assisted treatment (HAT)
Conclusion: opioid-dependence treatment
Stimulant-like medications
Miscellaneous medications
Conclusions: cocaine-dependence treatment
Medications for the treatment of cannabis dependence
Conclusion: cannabis-dependence treatment
Chapter 13 Evidence-based pharmacotherapy of Alzheimers disease
Neuropathology and neurochemistry
Current options for pharmacotherapy
Medications currently available
Memantine is a non-competitive NMDA receptor antagonist with moderate affinity
Current evidence to support efficacy
The evidence base to support an effect on cognition
A review of the research methodology
Evidence for cost-effectiveness
Evidence for non-cognitive measures of improvement
Management strategies for clinicians
Mild cognitive impairment
Mild to moderate dementia
Treatment resistance/non-response
Management of behavioral and psychological symptoms of dementia (BPSD)
Future therapeutic options
Chapter 14 Evidence-based pharmacotherapy of personality disorders
SChapter izotypal personality disorder (SPD)
Antisocial personality disorder (AsPD)
Borderline personality disorder
Tricyclic antidepressants (TCAs)
Monoamine oxidase inhibitors (MAOIs)
Selective serotonin reuptake inhibitors (SSRIs)
First-generation antipsychotics
Second-generation antipsychotics
Mood stabilizers and anticonvulsants
Avoidant personality disorder (AvPD)
Other personality disorders and maladaptive traits
Essential Evidence-Based Psychopharmacology
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.